TCR Cure

About TCR Cure

TCR Cure is a biotechnology startup that is revolutionizing the field of cancer treatment. The company specializes in patient-derived cell therapy innovation, focusing on the development of anticancer Natural Killer (NK) cell-based drugs. In simpler terms, they are creating new cancer treatments that use a patient's own cells to fight the disease.

The company's groundbreaking work is particularly focused on gynecological cancers. They have developed the first CAR-T cell immunotherapy for these types of cancers, which has shown promising results in pre-clinical trials and early clinical trials. CAR-T cell immunotherapy is a type of treatment that modifies a patient's own cells to fight cancer cells.

TCR Cure operates in the global biotechnology and healthcare market, serving patients suffering from various types of cancer. The company's business model revolves around the research, development, and commercialization of innovative cancer treatments. They generate revenue through the sale of these treatments once they have been approved for use in the healthcare industry.

The company was founded by a team of highly skilled professionals from around the world, including immunologists and virologists from Duke University and the University of Southern California. The scientific advisory team includes members from the American Academy of Sciences and the Chinese Academy of Sciences. The company currently employs over 150 full-time staff, including a scientific team from prestigious universities such as Peking University, Stanford University, Duke University, California Institute of Technology, and Harvard University.